Boussard & Gavaudan Investment Management’s Sage Therapeutics SAGE Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-614,939	Closed	-$5.61M	–	88
2025 Q2	$5.61M	Sell	614,939 -40,723	-6%	-$300K	0.72%	33
2025 Q1	$5.25M	Buy	+655,662	New	+$4.8M	0.82%	31

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Boussard & Gavaudan Investment Management's SAGE Position: Q3 2025 in Review

Boussard & Gavaudan Investment Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 614,939 shares — an estimated $5.61M sold.

Boussard & Gavaudan Investment Management first reported a position in SAGE in Q1 2025 and held it in 2 quarters. The position peaked at $5.61M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Boussard & Gavaudan Investment Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Boussard & Gavaudan Investment Management sold 614,939 Sage Therapeutics shares in Q3 2025, an estimated $5.61M.
Boussard & Gavaudan Investment Management first reported a position in Sage Therapeutics in Q1 2025 and held it in 2 quarters.
Boussard & Gavaudan Investment Management's Sage Therapeutics position peaked at $5.61M in Q2 2025.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q3 2025, filed 12 Nov 2025.